Pasithea expands PAS-004 trial to 18 months
Share
- Pasithea Therapeutics amended its Phase 1/1b trial protocol for its leading drug candidate.
- Shares of the biotechnology company traded down at $0.56 following the protocol revision.
- The clinical adjustments are designed to improve dose selection for future registrational studies.
Pasithea Therapeutics (NASDAQ:KTTA) expanded its Phase 1/1b PAS-004 clinical trial protocol to evaluate higher 24mg and 32mg dose levels.
The clinical-stage biotechnology company previously completed enrollment across its initial lower dose cohorts ranging from 4mg to 18mg.
The updated protocol expands magnetic resonance imaging alongside detailed tumor height and volume measurements while extending patient treatment up to 18 months.
The company remains on track to release its next interim neurofibromatosis type 1 data update during the fourth quarter of 2026.
The oncology platform previously secured a $60 million public offering in late 2025 to extend its corporate cash runway into 2028.
More from United States
AbbVie revenue increases 10.3% to $17.4 billion in third quarter
Sensient Q3 revenue rockets 10.6% to $455.8 million
Cameco Q3 adjusted loss reaches CA$2 million as uranium output falls
Kite Realty Q3 loss narrows to $13.3 million as NOI grows
Largo cuts 2026 vanadium production outlook to 9,500–10,500 tonnes
nVent Q3 sales jump 44% as shares fall despite higher revenue
